8th Jul 2013 07:00
Notice of Results
LONDON, UK, 08 July, 2013 - Skyepharma PLC (LSE: SKP), the expert oral and inhalation drug delivery company, will announce its interim results for the six months ended 30 June 2013, on Thursday 15 August 2013. A recording of the event will be available on the Company's website at www.skyepharma.com.
For further information please contact:
Skyepharma PLC | |
Peter Grant, Chief Executive Officer | +44 207 881 0524 |
| |
FTI Consulting | |
Julia Phillips/Susan Stuart/Natalie Garland-Collins | +44 207 831 3113 |
About Skyepharma PLC
Skyepharma combines proven scientific expertise with validated proprietary drug delivery technologies to develop innovative oral and inhalation pharmaceutical products. The Group is eligible for revenues from 14 approved products in the areas of inhalation, oral, topical and injectable drug delivery as well as generating income from the development of further products and technology licenses. The products developed by the Group are marketed throughout the world by big pharma as well as speciality pharmaceutical companies. For more information, visit www.skyepharma.com
Related Shares:
SKP.L